Pooled human gammaglobulin modulates surface molecule expression and induces apoptosis in human B cells

American Journal of Transplantation

Volumn 3, Issue 2, 2003, Pages 156-166

  Toyoda, Mieko ^a   Pao, Andy ^a   Petrosian, Anna ^a   Jordan, Stanley C ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Apoptosis; B lymphocyte; Cell surface molecules; Costimulation; Pooled human gamma globulin

Indexed keywords

ALLOANTIGEN; BLOCKING ANTIBODY; CD14 ANTIGEN; CD19 ANTIGEN; CD20 ANTIGEN; CD3 ANTIGEN; CD4 ANTIGEN; CD40 ANTIGEN; CD8 ANTIGEN; HUMAN IMMUNOGLOBULIN; IMMUNOGLOBULIN G; LYMPHOCYTE ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2;

ALLOIMMUNITY; ANTIGEN EXPRESSION; ANTIGEN RECOGNITION; APOPTOSIS; ARTICLE; AUTOIMMUNITY; B LYMPHOCYTE; CELL STRUCTURE; CELL SURFACE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOMODULATION; IMMUNOSTIMULATION; LYMPHOCYTE DEPLETION; MIXED LYMPHOCYTE REACTION; MONOCYTE; T CELL LYMPHOMA; T LYMPHOCYTE ACTIVATION;

ADULT; ANTIGENS, CD19; ANTIGENS, SURFACE; APOPTOSIS; B-LYMPHOCYTES; CELL CULTURE TECHNIQUES; GAMMA-GLOBULINS; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; LYMPHOCYTE CULTURE TEST, MIXED;

EID: 0037296040     PISSN: 16006135     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1600-6143.2003.00011.x     Document Type: Article

References (49)

1. Kaveri SV, Dietrich G, Hurez V, Kaszatchkine MD. Intravenous immunoglobulins (IVIg) in the treatment of autoimmune diseases. Clin Exp Immunol 1991; 86: 192-198.
2. Dwyer JM. Manipulating the immune system with immune globulin. N Engl J Med 1992; 326: 107-116.
3. Toyoda M, Zhang XM, Petrosian A, Wachs K, Moudgil A, Jordan SC. Inhibition of allospecific responses in the mixed lymphocyte reaction by pooled human gamma-globulin. Transplant Immunol 1994; 2: 337-341.
4. Admon D, Chen G, Fishbein MC et al. Posttransplant therapy using high-dose human immunoglobulin (Intravenous gammaglobulin) to control acute humoral rejection renal cardiac allograft recipients potential mechanism action. Transplantation 1998; 66: 800-805.
5. Jordan SC, Tyan D, Czer L, Toyoda M. Immunomodulatory actions of intravenous immunoglobulin (IVIG): potential applications in solid organ transplant recipients. Pediatr Transplant 1998; 2: 92-105.
6. Bartoni K, Budinger MD, Gale RP, Champlin RE. Intravenous immune globulin for prevention of cytomegalovirus infection and interstitial pneumonia after bone morrow transplantation. Ann Intern Med 1987; 106: 12-18.
7. Sivasai KS, Mohanakumar T, Phelan D, Martin S, Anstey ME, Brennan DC. Cytomegalovirus immune globulin intravenous (human) administration modulates immune response to alloantigens in sensitized renal transplant candidates. Clin Exp Immunol 2000; 119: 559-565.
8. Tyan DB, Li VA, Lawrence C, Trento A, Jordan SC. Intravenous immunoglobulin suppression of HLA alloantibody in highly sensitized transplant candidates and transplantation with a histoincompatible organ. Transplantation 1994; 57: 553-562.
9. Casadei DH, del Rial MC, Opelz G et al. A randomized and prospective study comparing treatment with high-dose intravenous immunoglobulin with monoclonal antibodies for rescue of kidney grafts with steriod-resistant rejection. Transplantation 2001; 71: 53-58.
10. Leffell MS, King KE, Burdick J et al. Plasmapheresis and intravenous immune globulin provides effective rescue therapy for refractory humoral rejection and allows kidneys to be successfully transplanted into cross-match-positive recipients. Transplantation 2000; 70: 887-895.
11. Steinman RM, Inaba K. Stimulation of the primary mixed leukocyte reaction. Crit Rev Immunol 1985; 5: 331-348.
12. Dubey C, Croft M. Accessory molecule regulation of naïve CD4 T cell activation. Immunol Res 1996; 15: 114-125.
13. Grewal IS, Flavell RA. The role of CD40 ligand in costimulation and T-cell activation. Immunol Rev 1996; 153: 85-106.
14. Toyoda M, Zhang X, Petrosian A, Galera OA, Wang SJ, Jordan SC. Modulation of immunoglobulin production and cytokine mRNA expression in peripheral blood mononuclear cells by intravenous immunoglobulin. J Clin Immunol 1994; 14: 178-189.
15. Lacroix-Desmazes S, Lefranc C, Desai R et al. Mechanism of action of intravenous immune globulin in immune-mediated diseases. Clin Exp Immunol 1996; 104 (Suppl. 1): 3-9.
16. Stangel M, Toyka KV, Gold R. Mechanism of high-dose intravenous immunoglobulins in demyelinating diseases. Arch Neurol 1999; 56: 661-663.
17. Chambers CA, Allison JP. Co-stimulation in T cell responses. Curr Opin Immunol 1997; 9: 396-404.
18. Ni K, O'Neill HC. The role of dendritic cells in T cell activation. Immunol Cell Biol 1997; 75: 223-230.
19. Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature 1998; 392: 245-252.
20. 2 fragments (5S IVIG) and Fc fragments. Evidence for post-transcriptional IL-2 modulation. Immunology 1997; 90: 212-218.
21. Toungous M, Denys C, Dupont E. Blockade of proliferation and tumor necrosis factor-alpha production occurring during mixed lymphocyte reaction by interferon-gamma-specific natural antibodies contained in intravenous immunoglobulins. Transplantation 1992; 62: 1292-1296.
22. Dietrich G, Mani JC, Klatzmann D, Kazatchkine MD. Anti-CD4 activity of normal human immunoglobulin G for therapeutic use. Therap Immunol 1994; 1: 269-277.
23. Vuist WM, Van Schaik IN, Van Lint M, Brand A. The growth arresting effect of human immunoglobulin for intravenous use is mediated by antibodies recognizing membrane glycolipids. J Clin Immunol 1997; 17: 301-310.
24. Lengagne R, Lefranc C, Cot S et al. Antibodies to a conserved region of HLA class I molecules, capable of modulating CD8 T cell-mediated function, are present in pooled normal immunoglobulin for therapeutic use. J Clin Invest 1996; 97: 865-869.
25. Marchalonis JJ, Kaymaz H, Dedeoglu F, Schluter SF, Yocum DE, Edmundson AB. Human autoantibodies reactive with synthetic autoantigens from T-cell receptor beta chain. Proc Natl Acad Sci USA 1992; 89: 3325-3329.
26. Bradley K, Ball C, Domenico J et al. Posttranscriptional regulation of T-cell IL-2 production by human pooled immunoglobulin. Clin Immunol Immunopathol 1997; 83: 77-85.
27. Andersson J, Skansen-Saphir U, Sparrelid E, Andersson U. Intravenous immune globulin affects cytokine production in T lymphocytes and monocytes/macrophages. Clin Exp Immunol 1996; 104 (Suppl.) (1): 10-20.
28. Bonnin E, Kazatchkine MD, Ruberti G et al. Therapeutic preparations of normal polyspecific IgG (IVIg) induce apoptosis in human lymphocytes and monocytes: a novel mechanism of action of IVIg involving the Fas apoptotic pathway. J Immunol 1998; 161: 3781-3790.
29. Schiff R. Half-life and clearance of pH 6.8 and pH 4.25 immunoglobulin G intravenous preparations in patients with primary disorders of humoral immunity. Rev Infect Dis 1986; 8 (Suppl. 4): S449-S456.
30. Pyun KH, Ochs HD, Oxelius VA et al. The half-lives of IgG subclasses and specific antibodies in patients with primary immunodeficiency who are receiving intravenously administered immunoglobulin. J Lab Clin Med 1988; 112: 634-640.
31. Sekul EA, Cupler EJ, Dalakas MC, Aseptic meningitis associated with high-dose intravenous immunoglobulin therapy: Frequency and risk factors. Ann Intern Med 1994; 121: 259-262.
32. Van Shaik IN, Lundkvist I, Vermeulen M, Brand A. Polyvalent immunoglobulin for intravenous use interferes with cell proliferation in vitro. J Clin Immunol 1992; 12: 325-334.
33. Hetts SW. To die or not to die: an overview of apoptosis and its role in disease. JAMA 1998; 279: 300-307.
34. Koffman BM, Dalakas MC. Effect of high-dose intravenous immunoglobulin on serum chemistry, hematology, and lymphocyte subpopulations: Assessments based on controlled treatment trials in patients with neurological diseases. Muscle and Nerve 1997; 9: 1102-1107.
35. Parry SL, Hasbold J, Holman M, Klaus GGB. Hypercross-linking surface IgM or IgD receptors on mature B cells induces apoptosis that is reversed by costimulation with IL-4 and anti-CD40. J Immunol 1994; 152:2821-2829.
36. Watanabe N, Nomura T, Takai T, Chiba T, Honjo T, Tsubata T. Antigen receptor cross-linking by anti-immunoglobulin antibodies coupled to cell surface membrane induces rapid apoptosis of normal spleen B cells. Scand J Immunol 1998; 47: 541-547.
37. Elkon KB, Marchak-Rothstein A. B cells in systemic autoimmune disease. recent insights from Fas-deficient mice and men. Curr Opin Immunol 1996; 8: 852-859.
38. Daniel PT, Krammer PH. Activation induces sensitivity toward APO-1(CD95)-mediated apoptosis in human B cells. J Immunol 1994; 152: 5624-5632.
39. Ashman RF, Peckham D, Stunz LL. Fc receptor off-signal in the B cell involves apoptosis. J Immunol 1996; 157: 5-11.
40. Pearse RN, Kawabe T, Bolland S, Guinamard R, Kurosaki T, Ravetch JV. SHIP recruitment attenuates Fc gamma RIIB-induced B cell apoptosis. Immunity 1999; 10: 753-760.
41. Ravetch JV, Lanier LL. Immune inhibitory receptors. Science 2000; 290: 84-89.
42. Pedersen AE, Bregenholt S, Johansen B, Skov S, Claesson MH. MHC-I-induced apoptosis in human B-lymphoma cells is dependent on protein tyrosine and serine/threonine kinases. Exp Cell Res 1999; 251: 128-134.
43. Truman JP, Ericson ML, Choqueux-Seebold CJM, Charron DJ, Mooney NA. Lymphocyte programmed cell death is mediated via HLA class II DR. Int Immunol 1994; 6: 887-896.
44. Samuelsson A, Towers TL, Ravetch JV. Anti-inflammatory activity of IVIG mediated through the inhibitory Fc receptor. Science 2001; 291: 484-486.
45. Rubin CM, Thompson CB. Apoptosis and diseases. Regulation and clinical relevance of programmed cell death. Annu Rev Med 1997; 48: 267-281.
46. Mountz JD, Zhou T, Su X, Wu J, Cheng J. The role of programmed cell death as an emerging new concept for the pathogenesis of autoimmune diseases. Clin Immunol Immunopath 1996; 80: S2-S14.
47. Visintin I, Flavell RA, Janeway Jr CA et al. The role of Fas in autoimmune diabetes. Cell 1997; 89: 17-24.
48. Roberts IA, Debatin KM, Fischer A et al. Mutations in Fas associated with human lymphoproliferative syndrome and autoimmunity. Science 1995; 268: 1347-1349.
49. Levine AJ. p53, the cellular gatekeeper for growth and division. Cell 1997; 88: 323-331.